 |
arGentisarGentis Pharmaceuticals a diversified specialty biopharmaceutical company seeking to license and commercialize therapies with demonstrated proof of concept in autoimmunity and ophthalmology. ARG201 an immunotherapy for systemic sclerosis, the lead therapeutic in autoimmunity, will enter Phase III trials in 2009. ARG101, the lead ophthalmology compound for dry eye syndrome, will enter Phase II in early 2009. | |
VaxentVaxent is an early stage vaccine development company located in Memphis. The Company's lead product in development is a subunit vaccine against group A streptococcus which has been tested in early stage human clinical trials. Vaxent plans to use its core competency in protein vaccine technology to advance its lead product in clinical testing, as well as develop other new vaccines against infectious diseases. | ||
To submit your idea for consideration:Click here to submit your idea.Contact us. |
||